| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer (NCT02571725) | New Mexico Cancer Research Alliance | 2016-02-23 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate (NCT02698657) | Astellas Pharma Global Development, Inc. | 2016-02-23 |
| Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer (NCT03276156) | Zhejiang Cancer Hospital | 2016-02-23 |
| Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer (NCT02734290) | Providence Health & Services | 2016-02-23 |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer (NCT02586675) | H. Lee Moffitt Cancer Center and Research Institute | 2016-02-23 |
| Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan (NCT02741310) | Amgen | 2016-02-22 |
| Colchicine for Diabetic Nephropathy Trial (NCT02442921) | Sheba Medical Center | 2016-02-22 |
| Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 (NCT02658916) | Biogen | 2016-02-22 |
| A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (NCT02671435) | MedImmune LLC | 2016-02-22 |
| A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution (NCT02688361) | GlaxoSmithKline | 2016-02-22 |
| Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder (NCT03102918) | Mclean Hospital | 2016-02-20 |
| Natreon Healthy Skin Study - PrimaVie Supplement (NCT02762032) | Ohio State University | 2016-02-20 |
| Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer (NCT02486796) | Midwestern Regional Medical Center | 2016-02-19 |
| First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders (NCT02719197) | Idorsia Pharmaceuticals Ltd. | 2016-02-19 |
| Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections (NCT02620774) | Hartford Hospital | 2016-02-19 |
| A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies (NCT02572687) | Eli Lilly and Company | 2016-02-19 |
| Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects (NCT02663687) | Shire | 2016-02-19 |
| A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer (NCT02512172) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-02-19 |
| Phase I Study of PDR001 in Patients With Advanced Malignancies. (NCT02678260) | Novartis Pharmaceuticals | 2016-02-19 |
| Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects (NCT02669667) | MedImmune LLC | 2016-02-18 |
| Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD (NCT02590692) | Regenerative Patch Technologies, LLC | 2016-02-16 |
| Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children (NCT02512926) | Stanford University | 2016-02-16 |
| Repeated Dosing Clinical Trial of HL151 (NCT02686294) | Hanlim Pharm. Co., Ltd. | 2016-02-16 |
| Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (NCT02973113) | Baylor College of Medicine | 2016-02-16 |
| Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients (NCT03282643) | Capital Medical University | 2016-02-16 |
| Phase I Study of MOv18 IgE (NCT02546921) | Cancer Research UK | 2016-02-16 |
| Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function (NCT02626312) | M.D. Anderson Cancer Center | 2016-02-15 |
| Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants (NCT02646891) | PATH | 2016-02-15 |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (NCT02453620) | National Cancer Institute (NCI) | 2016-02-12 |
| Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females (NCT02792517) | Amgen | 2016-02-12 |
| A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (NCT02592317) | Aragon Pharmaceuticals, Inc. | 2016-02-12 |
| Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (NCT02508038) | University of Wisconsin, Madison | 2016-02-12 |
| Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers (NCT02725112) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2016-02-12 |
| Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) (NCT02568683) | Gilead Sciences | 2016-02-11 |
| To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration (NCT02679729) | AstraZeneca | 2016-02-11 |
| An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (NCT02581631) | Bristol-Myers Squibb | 2016-02-11 |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors (NCT02573259) | Pfizer | 2016-02-10 |
| Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors (NCT02675491) | Daiichi Sankyo Co., Ltd. | 2016-02-10 |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer (NCT02635672) | Vincerx Pharma, Inc. | 2016-02-10 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects (NCT02632526) | AstraZeneca | 2016-02-10 |
| Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) (NCT02268253) | Stemline Therapeutics, Inc. | 2016-02-10 |
| Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT03243760) | GlaxoSmithKline | 2016-02-10 |
| Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer (NCT02826772) | Suzhou Kintor Pharmaceutical Inc, | 2016-02-10 |
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects (NCT03242239) | Alteogen, Inc. | 2016-02-09 |
| Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL (NCT02580552) | miRagen Therapeutics, Inc. | 2016-02-09 |
| Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth (NCT02569216) | NYU Langone Health | 2016-02-09 |
| A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR (NCT02687386) | Dr David Ziegler | 2016-02-08 |
| A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects (NCT02663089) | Theravance Biopharma | 2016-02-08 |
| DM-CHOC-PEN Plus Radiation for Brain Tumors (NCT03371004) | DEKK-TEC, Inc. | 2016-02-05 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 (NCT02509507) | Amgen | 2016-02-05 |
| MK-3475 Immunotherapy in Endometrial Carcinoma (NCT02630823) | Washington University School of Medicine | 2016-02-05 |
| Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis (NCT02459613) | Institut National de la Santé Et de la Recherche Médicale, France | 2016-02-05 |
| Study of a Single Dose of Danicopan in Healthy Participants (NCT04889677) | Alexion Pharmaceuticals, Inc. | 2016-02-04 |
| Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis (NCT02625246) | Marilyn Glassberg | 2016-02-04 |
| Neoadjuvant J591 Treatment for Prostate Cancer (NCT02693860) | Weill Medical College of Cornell University | 2016-02-04 |
| Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02254239) | Mayo Clinic | 2016-02-04 |
| Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) (NCT02501473) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-02-03 |
| Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer (NCT02546531) | Washington University School of Medicine | 2016-02-03 |
| Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors (NCT02639091) | Bayer | 2016-02-03 |
| Healthy Combine Study (NCT03136705) | Northwestern University | 2016-02-03 |
| Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA) (NCT02618941) | Affiris AG | 2016-02-02 |
| Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer (NCT02672865) | Loma Linda University | 2016-02-02 |
| Assessment of Any Potential Retinal Effects of Tafenoquine (TQ) (NCT02658435) | GlaxoSmithKline | 2016-02-02 |
| The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors (NCT02660034) | BeiGene | 2016-02-02 |
| Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors (NCT02705105) | Kyowa Kirin, Inc. | 2016-02-01 |
| A Study of Abemaciclib in Healthy Participants (NCT02677844) | Eli Lilly and Company | 2016-02-01 |
| MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults (NCT02674347) | Wockhardt | 2016-02-01 |
| Tau PET Imaging in Atypical Dementias (NCT03283449) | University of Chicago | 2016-02-01 |
| Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers (NCT02700347) | National University Hospital, Singapore | 2016-02-01 |
| A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) (NCT02653391) | Stealth BioTherapeutics Inc. | 2016-02-01 |
| Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate (NCT02671097) | Bayer | 2016-02-01 |
| Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil). (NCT02695004) | Dongkook Pharmaceutical Co., Ltd. | 2016-02-01 |
| Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany) (NCT02857946) | Genuine Research Center, Egypt | 2016-02-01 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035 (NCT02690142) | Affibody | 2016-02-01 |
| A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation (NCT02672839) | Ligand Pharmaceuticals | 2016-02-01 |
| Efficacy and Safety of Danzhen (NCT02645370) | Xijing Hospital | 2016-02-01 |
| SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis (NCT02696941) | University of Oxford | 2016-02-01 |
| Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (NCT02616874) | IrsiCaixa | 2016-02-01 |
| Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (NCT02381561) | National Cancer Institute (NCI) | 2016-02-01 |
| A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects (NCT02679469) | Otsuka Pharmaceutical Co., Ltd. | 2016-02-01 |
| Effects of GABA Modulator AZD7325 on Cutaneous Sensation (NCT02530580) | University College, London | 2016-02-01 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma (NCT02685670) | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 2016-02-01 |
| Limiting Chemotherapy Side Effects by Using Moxa (NCT02781155) | East and North Hertfordshire NHS Trust | 2016-02-01 |
| Validation of Aspiration Markers (NCT02301845) | Massachusetts General Hospital | 2016-02-01 |
| Metabolic Effects of Angiotensin-(1-7) (NCT02646475) | Vanderbilt University | 2016-02-01 |
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) (NCT02675946) | Curegenix Inc. | 2016-02-01 |
| A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. (NCT02601378) | Novartis Pharmaceuticals | 2016-02-01 |
| Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function (NCT02775981) | Pharmaceutical Project Solutions, Inc. | 2016-02-01 |
| Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis (NCT02694393) | Schmidhofer, Mark, MD | 2016-02-01 |
| Evaluation of MTA Versus Biodentine as Pulpotomy Agents in Immature First Permanent Molars (NCT03838094) | Gihan M Abuelniel ,PhD | 2016-02-01 |
| A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection (NCT02650427) | Institut National de la Santé Et de la Recherche Médicale, France | 2016-02-01 |
| Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age (NCT02326467) | Celeste Chandonnet | 2016-02-01 |
| A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (NCT02673736) | Plexxikon | 2016-02-01 |
| PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia (NCT02687984) | Indivior Inc. | 2016-02-01 |
| Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III (NCT02631928) | Julphar Gulf Pharmaceutical Industries | 2016-02-01 |
| PK of Rivaroxaban in Bariatric Patients - Extension (NCT02832947) | Insel Gruppe AG, University Hospital Bern | 2016-02-01 |
| FEIBA and Use of Blood Products in Cardiac Surgery (NCT02577614) | Oregon Health and Science University | 2016-02-01 |
| Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol (NCT02720224) | Estetra | 2016-02-01 |
| Phase 1 Study of NGM313 in Healthy Adult Participants (NCT02708576) | NGM Biopharmaceuticals, Inc | 2016-02-01 |